OA08724A - Treatment of human viral infections by dsRNA combined with viral inhibitors. - Google Patents

Treatment of human viral infections by dsRNA combined with viral inhibitors.

Info

Publication number
OA08724A
OA08724A OA59306A OA59306A OA08724A OA 08724 A OA08724 A OA 08724A OA 59306 A OA59306 A OA 59306A OA 59306 A OA59306 A OA 59306A OA 08724 A OA08724 A OA 08724A
Authority
OA
OAPI
Prior art keywords
viral
treatment
inhibitors
human
dsrna
Prior art date
Application number
OA59306A
Other languages
English (en)
French (fr)
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of OA08724A publication Critical patent/OA08724A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
OA59306A 1987-03-23 1988-03-23 Treatment of human viral infections by dsRNA combined with viral inhibitors. OA08724A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2882387A 1987-03-23 1987-03-23
US07/125,097 US4950652A (en) 1987-03-23 1987-11-25 dsRNAs for combination therapy in the treatment of viral diseases

Publications (1)

Publication Number Publication Date
OA08724A true OA08724A (fr) 1989-03-31

Family

ID=26704119

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59306A OA08724A (fr) 1987-03-23 1988-03-23 Treatment of human viral infections by dsRNA combined with viral inhibitors.

Country Status (21)

Country Link
US (1) US4950652A (enEXAMPLES)
EP (1) EP0286224B1 (enEXAMPLES)
JP (1) JP2656938B2 (enEXAMPLES)
KR (1) KR960013435B1 (enEXAMPLES)
CN (1) CN1049357C (enEXAMPLES)
AU (1) AU1256288A (enEXAMPLES)
CA (1) CA1316832C (enEXAMPLES)
DE (1) DE3876125T2 (enEXAMPLES)
DK (1) DK156688A (enEXAMPLES)
ES (1) ES2066782T3 (enEXAMPLES)
FI (1) FI881305A7 (enEXAMPLES)
GR (1) GR3006340T3 (enEXAMPLES)
HU (1) HUT46542A (enEXAMPLES)
IE (1) IE63823B1 (enEXAMPLES)
IL (1) IL85646A (enEXAMPLES)
NO (1) NO881246L (enEXAMPLES)
NZ (1) NZ223868A (enEXAMPLES)
OA (1) OA08724A (enEXAMPLES)
PH (1) PH23333A (enEXAMPLES)
PT (1) PT87039B (enEXAMPLES)
RU (1) RU2016572C1 (enEXAMPLES)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5091374A (en) * 1987-07-17 1992-02-25 Hem Research Inc. Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
US4960592A (en) * 1989-04-17 1990-10-02 Lanocare Laboratories Lanolin and lanolin oil skin treatment composition
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
EP0581906A4 (en) * 1991-04-16 1997-07-23 Hem Pharma Corp Abrogation of viral resistance to nucleoside analogues by double-stranded rnas
WO1993001717A1 (en) * 1991-07-16 1993-02-04 Hem Pharmaceuticals Corp. Modulation and diagnosis of cytokine dysfunctions
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
RU2123339C1 (ru) * 1996-06-18 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Противовирусное средство
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
JP2002515892A (ja) * 1997-01-17 2002-05-28 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド サイトカインが関係する疾患治療法
LT4475B (lt) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Informacinės ribonukleino rūgšties panaudojimas vaistinėse medžiagose, skirtose padidinti šios ribonukleino rūgšties koduojamo baltymo kiekį paciento ląstelėse
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2766711B1 (fr) * 1997-08-04 2001-02-02 Sod Conseils Rech Applic Produit comprenant au moins un arn double brin en association avec au moins un devire du 6-benzyluracile pour une utilisation therapeutique simultanee, separee ou etalee dans le temps
AR013269A1 (es) 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1555317B1 (en) 1998-03-20 2011-09-28 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs comprising the same
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
RU2172631C2 (ru) * 1999-10-08 2001-08-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Индуктор интерферона пролонгированного действия
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US20050070489A1 (en) * 2001-12-14 2005-03-31 Carter William A Use of dsrnas in strategic therapeutic intervention of highly active antiretroviral therapy
US7615227B2 (en) 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
EP3415625A1 (en) 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2368431A1 (en) 2002-04-04 2011-09-28 Coley Pharmaceutical GmbH Immunostimulatory G,U-containing oligoribonucleotides
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome
WO2005007831A2 (en) * 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
US20070219149A1 (en) * 2003-08-11 2007-09-20 The Research Foundation For Microbial Diseases Of Osaka University Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity
RU2272631C2 (ru) * 2004-04-20 2006-03-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Синергическая композиция для ингибирования вич
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
SI1957647T1 (sl) * 2005-11-25 2015-04-30 Zoetis Belgium S.A. Imunostimulatorni oligoribonukleotidi
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CN101437534A (zh) * 2006-03-08 2009-05-20 半球生物制药公司 口服干扰素的广谱免疫和抗病毒基因调节作用
CN101909625A (zh) * 2007-10-29 2010-12-08 希普拉有限公司 新型抗逆转录病毒组合
AU2009215128A1 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (en) * 1982-09-16 1989-07-19 Hem Research, Inc. Anti-proliferative action of dsnras on tumor cells
DE3608606A1 (de) * 1985-03-16 1986-09-18 The Wellcome Foundation Ltd., London 3'-azido-3'-deoxythymidin oder eine, ein pharmazeutisch vertraegliches derivat davon enthaltende pharmazeutische formulierung, verfahren zu ihrer herstellung und ihre verwendung
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
HUT46542A (en) 1988-11-28
EP0286224A2 (en) 1988-10-12
FI881305A0 (fi) 1988-03-18
CA1316832C (en) 1993-04-27
AU1256288A (en) 1988-09-22
DK156688A (da) 1988-09-24
DK156688D0 (da) 1988-03-22
RU2016572C1 (ru) 1994-07-30
JPS6425A (en) 1989-01-05
CN88101606A (zh) 1988-12-28
IE63823B1 (en) 1995-06-14
IE880839L (en) 1988-09-23
NO881246L (no) 1988-09-26
EP0286224A3 (en) 1988-12-07
US4950652A (en) 1990-08-21
PH23333A (en) 1989-07-14
KR960013435B1 (ko) 1996-10-05
KR880010777A (ko) 1988-10-24
IL85646A0 (en) 1988-08-31
EP0286224B1 (en) 1992-11-25
FI881305L (fi) 1988-09-24
DE3876125D1 (de) 1993-01-07
FI881305A7 (fi) 1988-09-24
ES2066782T3 (es) 1995-03-16
NO881246D0 (no) 1988-03-21
IL85646A (en) 1993-05-13
PT87039A (pt) 1988-04-01
DE3876125T2 (de) 1993-06-09
JP2656938B2 (ja) 1997-09-24
NZ223868A (en) 1991-02-26
CN1049357C (zh) 2000-02-16
PT87039B (pt) 1992-11-30
GR3006340T3 (enEXAMPLES) 1993-06-21

Similar Documents

Publication Publication Date Title
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
FI882456L (fi) Human proapolipoprotein a-i expression.
NO884124D0 (no) Kapasitivt maaleapparat for tomroms-andel.
DE19475001I2 (de) Anthelminthische Wirkstoffkombinationen.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
DE3788873D1 (de) Massagegerät.
DE3883966D1 (de) Behandlung durchlässiger membranen.
DE3875192D1 (de) Abgasbehandlung.
DK373688D0 (da) Behandlingsmetode
NO881255D0 (no) Behandling av fluider.
DE69108357D1 (de) Behandlung von verdünnten säurehaltigen Lösungen.
ES2012433A4 (es) Descafeinizacion de estractos acuosos.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
DE3869828D1 (de) Stabilisierung von aminalane.
IT8420712A0 (it) Trattamento delle infezioni erpetiche.
DK196588A (da) Forbinding
ZA881639B (en) Treatment of human viral infection by dsrna combined with viral inhibitors
FI884069A7 (fi) Kaksijuosteisen RNA:n puutostilojen diagnoosi ja käsittely.
ATE82688T1 (de) Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
FI871296A7 (fi) Hieromalaite.
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
NO893346D0 (no) Saarheling.
FI841831A0 (fi) Baeranordning foer urinpaose.
ATE70971T1 (de) Foerderung der heilung von meniskusgewebe.